

TR-14035

Catalog No: tcsc1812



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

232271-19-1

Formula:

$C_{24}H_{21}Cl_2NO_5$

Pathway:

Cytoskeleton

Target:

Integrin

Purity / Grade:

>98%

Solubility:

DMSO : \geq 41 mg/mL (86.44 mM)

Observed Molecular Weight:

474.33

Product Description

TR-14035 is a a dual $\alpha4\beta7$ (IC₅₀=7 nM)/ $\alpha4\beta1$ (IC₅₀=87 nM) integrin antagonist .


IC50 Value: $\alpha(4)\beta(7)/\alpha(4)\beta(1)=7/87$ nM [1]

Target: integrin

TR14035 blocked the binding of human $\alpha(4)\beta(7)$ to an (125)I-MAdCAM-Ig fusion protein with IC(50) values of 0.75 nM. TR14035 blocked binding of human $\alpha(4)\beta(7)$ -expressing RPMI-8866 cells or murine mesenteric lymph node lymphocytes to MAdCAM-Ig with IC(50) values of 0.1 μ M [2].

TR14035 blocked adhesion to HEVs [ED(50) of 0.01-0.1 mpk i.v.].

TR-14035 was taken up by rat and human hepatocytes by an apparently single saturable mechanism with K(m) of 6.7 and 2.1 μ M, respectively, and taurocholate and digoxin reduced this uptake [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!